John Bruning

John Bruning is a biophysicist with extensive experience in biophysical and structural characterization of small molecule-protein interactions, as well as in silico techniques such as molecular modeling and docking. They completed a Ph.D. in Pharmaceutical Sciences from the University of California, San Francisco, where they uncovered novel regulatory mechanisms and developed synthetic small-molecule agonists. Their postdoctoral research at Stanford University focused on implementing drug discovery approaches against lipid kinases, successfully predicting fragment binding and lead-like molecules. Currently, John serves as a Principal Scientist at Neomorph, Inc., following previous roles at Treeline Biosciences and Genentech.